A case of atypical cells in the urinary sediment of a patient with methotrexate-associated lymphoproliferative disorders

DOI Web Site
  • NAGAKAWA Syogo
    Department of Clinical Laboratory, Fukuoka University Hospital
  • SAKAI Rumiko
    Department of Clinical Laboratory, Fukuoka University Hospital
  • ISHIKAWA Michiko
    Department of Clinical Laboratory, Fukuoka University Hospital
  • SHIMADA Hirofumi
    Department of Clinical Laboratory, Fukuoka University Hospital
  • OGAWA Masahiro
    Department of Clinical Laboratory, Fukuoka University Hospital Clinical Inspection Medicine Lecture, Faculty of Medicine, The Fukuoka University

Bibliographic Information

Other Title
  • メトトレキサート関連リンパ増殖性疾患患者の尿沈渣中に異型細胞を認めた1症例
  • メトトレキサート カンレン リンパ ゾウショクセイ シッカン カンジャ ノ ニョウチンサチュウ ニ イケイ サイボウ オ ミトメタ 1 ショウレイ

Search this article

Abstract

<p>Although methotrexate (MTX) is a highly effective drug in rheumatoid arthritis (RA) patients, it also has various side effects. Lymphoproliferative disorders (LPDs) are one of them, and they have a unique feature of disappearing when MTX is discontinued. We encountered a case in which LPD developed in an RA patient who was using MTX, and atypical cells that were considered to be derived from hematopoietic tumors were found in the patient’s urine. There have been very few reports of MTX-LPD onset in the kidney, and it was important to confirm the patient’s medical information and background.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top